Emulate has announced its launch with a $12 million Series A financing to commercialize an automated ‘Organs-on-Chips’ platform. The platform mimics true human physiology so that responses to medicines, chemicals and diseases can be accurately predicted. Emulate will use the proceeds from the financing to advance the first commercial applications of its automated platform through co-innovation with corporate and clinical clients and through internal development programs. The company’s initial focus will be use of Organs-on-Chips to provide more rapid and accurate evaluation of human responses to drugs and cosmetics, and to create new clinical guidance tools for personalized therapies. The round was led by NanoDimension, with additional participation by Cedars-Sinai Medical Center.